Drugs / Neovasculgen
Neovasculgen
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02352649 | Apr 2015 → Mar 2016 | peripheral nerve lesion | Artgen Biotech | Unknown | No outcome recorded |
| Phase 1/2 | NCT02356809 | Mar 2015 | Raynaud disease | Artgen Biotech | Unknown | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07391306 | Feb 2024 → May 2027 expected | interstitial cystitis | JSC NextGen | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07459790 | Dec 2023 → Oct 2027 expected | interstitial cystitis | JSC NextGen | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03068585 | Feb 2010 → Jun 2011 | peripheral arterial disease | Artgen Biotech | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07391319 | Feb 2025 → Mar 2027 expected | diabetes mellitus, ulcer of lower limbs | JSC NextGen | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02369809 | Sep 2012 → Jan 2017 | limb ischemia | Artgen Biotech | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02538705 | Aug 2015 → Jan 2016 | ulcer of lower limbs | Artgen Biotech | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neovasculgen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03068585 ↗ |
| Known as | Cambiogeneplasmid | “Neovasculgen (Cambiogeneplasmid)” NCT03068585 ↗ |
| Known as | pCMV-VEGF165 | “Double-blind, Placebo-controlled, Adaptive, Multicenter, Prospective, Randomized, Comparative, Parallel-group Study of the Efficacy and Safety of Neovasculgen (Plasmid...” NCT07459790 ↗ |
| Known as | pl-vegf165 | “The purpose of this study is to determine whether pl-vegf165 (Neovasculgen) is effective in the treatment of digital ulcers related to secondary Raynaud's phenomenon associated...” NCT02356809 ↗1“The purpose of this study is to determine safety and efficacy of pl-vegf165 ("Neovasculgen") for regeneration of peripheral nerve.” NCT02352649 ↗ |
| Modality | Other / unclassified | “Plasmid Supercoiled Deoxyribonucleic Acid pCMV-VEGF165” NCT07391306 ↗ |
| Route | Intramuscular | “The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.” NCT02356809 ↗ |